Genkyotex is working on a second program to develop selective NOX1 inhibitors. NOX1 is an NADPH oxidase isoform that is known to play a key role in cell proliferation processes, inflammation and pain. After a screening campaign on 150,000 molecules, a number of selective NOX1 inhibitors were identified, followed by the launch of an optimization process where its physicochemical, pharmacokinetic and ADME (Absorption, Distribution, Metabolism, Excretion) properties were improved. The Company's goal is to identify and develop several selective NOX1 inhibitors with different use profiles that can be administered orally, applied topically or, for central programs, can cross the blood-brain barrier.

Genkyotex is currently conducting preclinical studies to define the high-priority clinical indications for these selective NOX1 inhibitors. The indications currently under consideration include rheumatic diseases such as osteoarthritis and inflammatory arthritis, inflammatory skin disorders, eye diseases and various forms of inflammatory pain. Genkyotex is also exploring the role of NOX1 in central disorders, such as Parkinson's disease.